» Articles » PMID: 19384894

Stringent Testing Identifies Highly Potent and Escape-proof Anti-HIV Short Hairpin RNAs

Overview
Journal J Gene Med
Date 2009 Apr 23
PMID 19384894
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: RNA interference (RNAi) is a cellular mechanism that can be induced by small interfering RNAs to mediate sequence-specific gene silencing by cleavage of the targeted mRNA. RNAi can be used as an antiviral approach to silence the human immunodeficiency virus type 1 (HIV-1) through stable expression of short hairpin RNAs (shRNAs). Previously, we used a co-transfection assay in which shRNA constructs were transfected with an HIV-1 molecular clone to identify 20 shRNA inhibitors that target highly conserved HIV-1 sequences.

Methods: In the present study, we selected the most potent shRNAs to formulate a combinatorial shRNA therapy and determine the best and easiest method for antiviral shRNA selection. We performed transient inhibition assays with either a luciferase reporter or HIV-1 molecular clone and also infected shRNA-expressing T cell lines with HIV-1 and monitored virus replication. The latter assay allows detection of viral escape. In addition, we also tested shRNA-expressing T cells upon challenge with increasing dosages of HIV-1, and measured the dose required to result in massive virus-induced syncytia formation in this 2-week assay.

Results: Extended culturing selected three highly effective shRNAs that do not allow viral replication for more than 100 days. This difference in potency was not observed in the transient co-transfection assays. The use of increased dosages of HIV-1 selected the same highly potent shRNAs as the laborious and extended escape study.

Conclusions: These highly potent shRNAs could be used for a clinical vector and the comparison of the developed assays might help other researchers in their search for antiviral shRNAs.

Citing Articles

RNA Interference Therapies for an HIV-1 Functional Cure.

Scarborough R, Gatignol A Viruses. 2017; 10(1).

PMID: 29280961 PMC: 5795421. DOI: 10.3390/v10010008.


CRISPR/Cas9-Mediated Immunity to Geminiviruses: Differential Interference and Evasion.

Ali Z, Ali S, Tashkandi M, Zaidi S, Mahfouz M Sci Rep. 2016; 6:26912.

PMID: 27225592 PMC: 4881029. DOI: 10.1038/srep26912.


CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.

Wang G, Zhao N, Berkhout B, Das A Mol Ther. 2016; 24(3):522-6.

PMID: 26796669 PMC: 4786927. DOI: 10.1038/mt.2016.24.


Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

Mendez C, Ahlenstiel C, Kelleher A World J Virol. 2015; 4(3):219-44.

PMID: 26279984 PMC: 4534814. DOI: 10.5501/wjv.v4.i3.219.


Bone Marrow Gene Therapy for HIV/AIDS.

Herrera-Carrillo E, Berkhout B Viruses. 2015; 7(7):3910-36.

PMID: 26193303 PMC: 4517133. DOI: 10.3390/v7072804.